MERCK KGAA |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 141.85 EUR | +0.18% |
|
-0.77% | -1.56% |
| 12-02 | MERCK KGAA : Receives a Buy rating from DZ Bank | ZD |
| 11-27 | Reckitt Benckiser adds Bacardi CEO and ex-Merck CEO to board | AN |
Summary: Merck KGaA
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Highlights: Merck KGaA
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's high margin levels account for strong profits.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses: Merck KGaA
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- The group usually releases earnings worse than estimated.
Ratings Chart: Merck KGaA
Source: Surperformance
ESG chart: Merck KGaA
Source: Refinitiv
| Composite Fundamentals | Composite Valuation | Composite Momentum | Capi. ($) | ||
|---|---|---|---|---|---|
| 64.96B | |||||
| 8.41B | |||||
| 6.18B | |||||
| 6.13B | |||||
| 5.79B | |||||
| 3.2B | |||||
| 2.26B | |||||
| - | 2.02B | ||||
| Average | 12.37B | ||||
| Weighted average by Cap. |
Investor Rating
Trading Rating
ESG Refinitiv
A
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- MRK Stock
- Ratings Merck KGaA
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition